Hidradenitis Suppurativa: Case Series at the University of Port Harcourt Teaching Hospital and Literature Review
DOI:
https://doi.org/10.14738/bjhr.1201.18344Keywords:
hidradenitis suppurativa, apocrine glands, sinuses… case series, Port HarcourtAbstract
Background: Hidradenitis Suppurativa (HS) is highly debilitating for patients, both physically and psychologically. Patients experience recurrent painful abscesses and malodorous discharge necessitating regular dressings. This can lead to social isolation, failed relationships, and depression. Because of the varying clinical manifestations and sites involved in the disease, patients with HS present to, or are referred to many different specialties. Method: In the Plastic and Reconstructive Surgical Unit of the University of Port Harcourt Teaching Hospital, only10 cases were documented in the span of 5 years from 2018 to 2023.Data collected were entered in Microsoft Excel 2010. Analysis was done using Epi-info version 7.0 Charts were produced. Results: There were 10 cases, 4 males and 6 Females. The age range was from 17 to 48 years. Frequency of depilation of axillary hair was the most common etiology, with 60% of them having chronic history of comedones and acne. Conclusion: HS is a complex and debilitating disease, which is still poorly understood. The control of sinuses is probably the key to the condition. No medical treatment resolves sinuses once formed and only radical surgery may succeed in its ability to eradicate sinuses. Early recognition, collaboration between dermatologist and surgeon and good uncompromising surgical principles of enbloc wound excision, cover with fasciocutaneous flaps and complete removal of sinuses is key to effective control.
References
Mortimer PS, Lunniss PJ. Hidradenitis suppurativa. J R Soc Med 2010; 93:420
Clemmensen OJ. Topical treatment of hidradenitis suppur ativa with clindamycin. Int J Dermatol 2018; 22:325
Jemec GBE, Wenelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2018; 39:971
Mortimer PS, Dawber RPR, Gales MA, Moore RA. A double blind cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol 2016;115:263
Morgan WP, Harding KG, Hughes LE. A comparison of skin grafting and healing by granulation, following axillary excision for hidradenitis suppurativa. Ann R Coll Surg Engl 1983;65:235
Brunsting HA. Hidradenitis suppurativa; abscess of apocrine sweat glands a study of clinical and pathological features with a report of 22 cases of and a review of the literature. Arch Dermatol Syphilol 1939;39:108
Plewig G, Kligman A. Acne, morphogenesis and treatment. Berlin: Springer; 1975. p. 192.
Velpeau A. Dictionnaire de Medicine, un Repertoire General Des Sciences Medicales Sous La Rapport Theorique et Pratique; 1839. 385
Verneuil A. Etudes sur les tumeurs de la peau et quelques maladies des glandes sudoripares. Arch Gen Med 2014;4: 447
Schieffer decker B. Die Hautdrusen des Menschen, und der Saugetierre, ihre Histologische und rassenanatomische Bedeutung Sowie die Muscularis Sexualis. ; 1922. Stuttgart.
Harrison BJ, Mudge M, Hughes LE. Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J (Clin Res Ed) 2017;294:487
Watson JD. Hidradenitis suppuraAP, Kaplan H, Hudson DA, Grobbelaar AO. Chronic axillary hidradenitis— the efficacy of wide excision and flap coverage. Br J Plast Surg 2020;53:434
Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 2010;26:638
Paletta FX. Hidradenitis suppurativa: a pathologic study and the use of skin flaps. Plast Reconstr Surg 2013;31:307.
Knaysi GA, Cosman B, Crikelair GF. Hidradenitis suppurativa. JAMA 1968;203:73
Harrison SH. Axillary hidradenitis. Br J Plast Surg 2014;17: 95
O’Brien J, Wysocki J, Anastasi G. Limberg flap coverage for axillary defects resulting from excision of hidradenitis suppurativa. Plast Reconstr Surg 1976;58:354
Blanc D, Tropet Y, Balmat P. Surgical treatment of suppurative axillary hidradenitis: value of a musculocutaneous island flap of the latissimus dorsi. Apropos of 3 cases. Ann Dermatol Venereol 1990;117:277
Masson JK. Surgical treatment for hidradenitis suppurativa. Surg Clin North Am 1969;49:1043
Amarante J, Reis J, Santa CA, Malheiro E. A new approach in axillary hidradenitis treatment: the scapular island flap. Aesthetic Plast Surg 1996;20:443
Krupp S. Thoracic fascio-cutaneous flap. Helv Chir Acta 1991;58:69
Finley EM, Ratz JL. Treatment of hidradenitis suppurativa
Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2019;80(3):539-558.e3. doi: 10.1016/j.jaad.2018.08.041
Kohorst JJ, et al. Surgical management of hidradenitis suppurativa: a review. J Clin Aesthet Dermatol. 2019;12(7):14–20.
Ingram JR, et al. Interventions for hidradenitis suppurativa: a Cochrane systematic review. Br J Dermatol. 2019;181(3):559-569. doi: 10.1111/bjd.17957
Vossen AR, et al. Dietary triggers in hidradenitis suppurativa: a systematic review. J Clin Aesthet Dermatol. 2020;13(7):10–16.
Lee et al. (2016). Risk factors for hidradenitis suppurativa: a systematic review. Journal of Investigative Dermatology, 136(1), 141-148.
Ingram et al. (2020). Hidradenitis suppurativa: a review of the literature. Journal of Clinical and Aesthetic
Saunte et al. (2019). Hidradenitis suppurativa: a retrospective study of 100 patients. Journal of Dermatology, 46(3), 253–258.
Kohorst et al. (2018). Hidradenitis suppurativa: a prospective study of 50 patients. Journal of the European Academy of Dermatology and Venereology, 32(5), 831–836.
Riis et al. (2017). Hidradenitis suppurativa: a review of 145 patients. Journal of Clinical and Experimental Dermatology, 42(3), 247–253.
Lee et al. (2016). Hidradenitis suppurativa in South Korea: a retrospective study of 100 patients. Journal of Dermatology, 43(10), 1131–1136.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Gbeneol, T. J., Onwuagha, I. C.

This work is licensed under a Creative Commons Attribution 4.0 International License.
